Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated
in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated …

The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …

Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …

Purpose: Autologous chimeric antigen receptor T (CAR-T) cell therapy is an effective
treatment for relapsed/refractory acute lymphoblastic leukemia (r/r ALL). However, certain …

Acute lymphoblastic leukemia (ALL) is a cancer-specific lymphoid cell. Induction and
consolidation chemotherapy alone or in combination with different therapeutic approaches …

At present, the idea of genome modification has revolutionized the modern therapeutic
research era. Genome modification studies have traveled a long way from gene …

Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …

Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-
cells is limited by antigen modulation, which may be overcome with combinatorial targeting …

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

In the past several decades, the development of cancer therapeutics has largely focused on
precision targeting of single cancer-associated molecules. Despite great advances, such …